Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥6,754 | ¥8,450 | ¥6,644 | ¥6,852 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Cost of Goods Sold | ¥2,673 | ¥1,858 | ¥1,615 | ¥2,127 |
| Gross Profit | ¥4,081 | ¥6,592 | ¥5,029 | ¥4,725 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | ¥3,726 | ¥3,666 | ¥3,808 | ¥3,299 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥3,844 | ¥3,865 | ¥3,701 | ¥4,298 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥2,238 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | -¥295 |
| Operating Expenses | ¥7,570 | ¥7,531 | ¥7,509 | ¥7,302 |
| Operating Income | -¥3,489 | -¥939 | -¥2,480 | -¥1,683 |
| % Margin | -51.7% | -11.1% | -37.3% | -24.6% |
| Other Income/Exp. Net | ¥373 | -¥627 | ¥324 | -¥686 |
| Pre-Tax Income | -¥3,116 | -¥1,566 | -¥2,156 | -¥2,369 |
| Tax Expense | -¥1,444 | ¥811 | -¥1,396 | -¥1,034 |
| Net Income | -¥1,672 | -¥2,377 | -¥760 | -¥1,335 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -18.48 | -26.38 | -8.45 | -14.86 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| Weighted Avg Shares Out | 90 | 90 | 90 | 90 |
| Weighted Avg Shares Out Dil | 90 | 90 | 90 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥239 | ¥255 | ¥286 | ¥412 |
| Interest Expense | ¥204 | ¥1,258 | ¥249 | ¥204 |
| Depreciation & Amortization | ¥1,106 | ¥1,095 | ¥1,082 | ¥1,003 |
| EBITDA | -¥1,806 | ¥787 | -¥825 | -¥1,574 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |